A therapy demonstrated to permanently halt early-stage Alzheimer's progression receives FDA approval before 20

Question

Six frontier AI models put this at 5% by 2 Nov 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

5% — the median of 6 frontier models, resolving by 2036-11-02.

Answer

Gemini (Google): 4% — Halting neurodegeneration permanently requires cellular restoration or complete arrest that no current clinical pipeline candidate can deliver. Monoclonal antibodies like lecanemab merely slow decline by 27-35% rather than permanently stopping tau-driven downstream cascades. FDA approval before 2032 requires a drug entering Phase 3 by 2027, yet zero active Phase 2 candidates demonstrate indefinite disease arrest. Proving 'permanent' arrest in early Alzheimer's demands multi-year longitudinal trials that cannot finish and clear FDA review in 5 years.

Answer

Claude (Anthropic): 4% — Requires a cure-level therapy proven to permanently halt neurodegeneration, far beyond current anti-amyloid drugs like lecanemab. Current FDA-approved drugs only modestly slow decline, not halt it permanently, and no drug in late-stage trials claims permanent cessation. Demonstrating 'permanent halt' requires long-term follow-up data (likely 10+ years) that would be hard to generate and validate before 2036. Alzheimer's biology is multifactorial (amyloid, tau, inflammation, vascular), making a single curative therapy unlikely within this timeframe absent a major scientific…

Answer

GPT (OpenAI): 7% — It turns on whether any disease-modifying candidate can show durable cessation, not merely slowed decline, in long trials. FDA would need convincing controlled evidence of indefinite stability in preclinical or early Alzheimer’s, likely over several years. Recent approvals such as lecanemab and donanemab modestly slow decline; no therapy has demonstrated permanent arrest of neurodegeneration. A validated biomarker tightly predicting lifelong clinical stability, or striking long-term trial results by 2030, would sharply raise the odds.

Answer

Grok (xAI): 5% — No late-stage asset can generate multi-year ‘indefinite halt’ data and FDA review by 2031. FDA needs Phase-3 plus ≥3–5 y follow-up showing zero progression in MCI/preclinical AD; current anti-amyloid/tau programs only slow decline ~25–30 %. From 2026, even an already-enrolling pivotal trial cannot finish, unblind, and file before ~2033; gene/siRNA or regenerative approaches remain Phase 1/2. Historic AD DMT success rate is <1 %; nothing in the 2026 pipeline claims or is powered for permanent arrest, so the case sits far below even modest-DMT base rates.

Answer

DeepSeek (DeepSeek): 9% — No mechanism has ever shown permanent halt in trials; approval by 2032 needs a phase 3 win that doesn't yet exist. Lecanemab and donanemab cleared FDA in 2023-24 but only slow decline ~27-35%, not halt it, so the bar is a different mechanism entirely. Anti-amyloid, tau, and anti-inflammatory pipelines have repeatedly failed phase 3 halting endpoints; no candidate is currently in phase 3 with a permanent-halt claim. A single positive phase 3 with a durable plateau on CDR-SB over 18+ months would shift this sharply, but none is reading out before 2029.

Answer

Qwen (Alibaba): 2% — No drug in any phase has shown complete cessation of neurodegeneration, let alone with durability data to support 'permanent.' Lecanemab and donanemab slow decline ~27-35%; no candidate in Phase 3 as of 2026 targets full arrest, and demonstrating 'indefinite' halting requires follow-up longer… FDA has never approved a disease-modifying neurodegeneration drug with a claim of permanent halt; the evidentiary bar would require multi-year post-treatment data… A surprise gene therapy or antisense oligonucleotide showing complete biomarker and clinical arrest could shift this, but no such candidate is in registrational trials…

A therapy demonstrated to permanently halt early-stage Alzheimer's progression receives FDA approval before 2032.

What each one said

A therapy demonstrated to permanently halt early-stage Alzheimer's progression receives FDA approval before 2032.

The World Health Organization declares a new global pandemic before 2032.

An FDA-approved treatment that halts or reverses cognitive decline in Alzheimer's disease is available before 2035.

A universal curative treatment for all major types of cancer is approved before 2050.

The University of Oxford conducts its space medicine program as announced between November 16 and November 20, 2026.